Phreesia (NYSE:PHR) Sets New 12-Month Low Following Weak Earnings

Shares of Phreesia, Inc. (NYSE:PHR) hit a new 52-week low during trading on Tuesday after the company announced weaker than expected quarterly earnings. The company traded as low as $8.23 and last traded at $8.0690, with a volume of 261246 shares trading hands. The stock had previously closed at $11.41.

The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The business had revenue of $127.07 million for the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. Phreesia’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.11) earnings per share.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Several brokers kept buy/outperform stances or price targets above the current level, implying upside and supporting a rebound: BMO kept an “outperform” rating with a $14 target. Benzinga
• Positive Sentiment: Canaccord Genuity reiterated a “buy” rating despite lowering its target to $22, signaling confidence in longer-term upside. Benzinga
• Positive Sentiment: Needham kept a “buy” rating while cutting its target to $14, another vote that some analysts view the stock as attractive after the pullback. Benzinga
• Neutral Sentiment: Company results: Q4 revenue of about $127M (+15.9% YoY) and fiscal-year operating/cash-flow milestones were reported, but quarter-level EPS and metric headlines were mixed across sources (some headline misses, some call transcripts indicating beats), leaving clarity for investors dependent on the call/slide details. Press Release / Slide Deck
• Negative Sentiment: Management cut FY2027 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the earlier steep share decline. Benzinga Guide Cut Article
• Negative Sentiment: Multiple analysts downgraded or cut price targets after the guidance cut — Robert W. Baird and Citigroup reaffirmed neutral/hold views with $10 targets, and Truist held at $11 — increasing near-term selling pressure and lowering consensus valuation expectations. TickerReport
• Negative Sentiment: Market reaction: headlines show shares plunged ~22–26% immediately after the results/guidance, indicating heightened short-term risk and potential for continued volatility. MSN

Analyst Upgrades and Downgrades

PHR has been the topic of a number of analyst reports. Stephens cut their price target on Phreesia from $32.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday. Robert W. Baird restated a “neutral” rating and set a $10.00 price objective (down from $25.00) on shares of Phreesia in a research note on Tuesday. Wall Street Zen lowered Phreesia from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 8th. Wells Fargo & Company reduced their target price on shares of Phreesia from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, March 26th. Finally, DA Davidson lowered their price target on shares of Phreesia from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Thirteen investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Insider Transactions at Phreesia

In other Phreesia news, CFO Balaji Gandhi sold 3,829 shares of the stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total value of $43,114.54. Following the completion of the sale, the chief financial officer directly owned 146,740 shares in the company, valued at approximately $1,652,292.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Allison C. Hoffman sold 6,176 shares of the business’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $11.97, for a total value of $73,926.72. Following the sale, the general counsel owned 163,485 shares in the company, valued at $1,956,915.45. The trade was a 3.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 70,358 shares of company stock worth $1,123,569. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Granahan Investment Management LLC raised its stake in Phreesia by 73.8% in the 4th quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock worth $40,601,000 after acquiring an additional 1,018,987 shares during the last quarter. Prosight Management LP acquired a new position in shares of Phreesia in the fourth quarter valued at about $16,533,000. Millennium Management LLC raised its stake in shares of Phreesia by 730.7% in the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after purchasing an additional 936,033 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Phreesia during the fourth quarter worth about $15,213,000. Finally, Greenhouse Funds LLLP boosted its position in Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after buying an additional 557,265 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Trading Down 24.9%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The company has a market cap of $516.87 million, a price-to-earnings ratio of -84.27 and a beta of 0.67. The company’s fifty day moving average is $12.51 and its two-hundred day moving average is $17.68.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.